Researchers found that a new formulation of LEQEMBI, a treatment for Alzheimer’s disease, is under review by the FDA for a subcutaneous injection that could be given once a week. This new delivery method aims to make it easier for patients to receive treatment. The FDA has extended its review period by three months, moving the decision date to August 24, 2026, to allow for a thorough evaluation of additional information requested.

This development is significant for people concerned about Alzheimer’s and cognitive health. If approved, the once-weekly injection could simplify the treatment process, potentially improving adherence to medication regimens. LEQEMBI has already received approval for subcutaneous maintenance dosing, which means that if the starting dose is also approved, it could provide a more convenient option for those managing Alzheimer’s. Given that Alzheimer’s affects millions of older adults, this could represent a meaningful advancement in treatment options.

The current review is based on a comprehensive clinical data package, but it is important to note that this is still an early-stage evaluation. The FDA has not raised any concerns about the drug’s approval so far, but the final decision will depend on the thoroughness of the new information being reviewed. As of now, LEQEMBI is already approved in 53 countries, indicating a growing recognition of its potential benefits.

Source: longevity.technology